Board of directors

Pablo Legorreta

Founder & Chief Executive Officer

Pablo is the founder, CEO and Chairman of Royalty Pharma plc. Since its founding in 1996, Royalty Pharma has been the pioneer and market leader in royalty funding of life science innovation. The company’s collaborations span the entire research and development ecosystem, from academic institutions, research hospitals and not-for-profits to small- and mid-cap biotechnology companies and global pharmaceutical companies. To date, Royalty Pharma has deployed more than $20 billion of capital to advance innovation in the biopharmaceutical industry.

Pablo is a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. He is also a co-founder of ProKidney, LLC, a biotech company developing pioneering therapies that have the potential to change the lives of people with chronic kidney disease.

Pablo is also the founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities.

Pablo serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, the Hospital for Special Surgery, Pasteur Foundation (US), Open Medical Institute and Park Avenue Armory.

Prior to founding Royalty Pharma, Pablo was an investment banker at Lazard Frères in Paris and New York.

Bonnie Bassler, PhD

Bonnie Bassler, PhD has been a member of our board of directors since June 2020. Bonnie currently serves in several roles at Princeton University, including, Chair of the Department of Molecular Biology since 2013, associated faculty member of the Department of Chemistry since 2010, Investigator at the Howard Hughes Medical Institute since 2005, Professor in the Department of Molecular Biology since 1994, and associate faculty member of the Princeton Environmental Institute since 1996. Previously, Bonnie served as the Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013. Bonnie has served as a board member of Kaleido Biosciences, Inc. since 2018, as a board member of Regeneron Pharmaceuticals, Inc. since 2016, and as a Trustee of the Alfred P. Sloan Foundation since 2014, and previously served as a board member of Sanofi from November 2014 to September 2016. Bonnie served as a board member of the American Association for the Advancement of Science from January 2012 to December 2016. She was a member of the National Science Board from January 2010 until May 2016. Bonnie has been elected to the National Academy of Sciences, the National Academy of Medicine, and the Royal Society, among other honorific organizations. She received a BS in biochemistry from the University of California-Davis and a PhD in biochemistry from the John Hopkins University.

Vlad Coric, MD

Vlad Coric, MD serves as Chief Executive Officer and as a director of Biohaven (NYSE: BHVN). He has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec® ODT (rimegepant; oral calcitonin related peptide antagonist), Zavzpret® (zavegepant; intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor) and Sunvepra® (asunaprevir; NS3 inhibitor). From January 2007 to September 2015, he served as a group director of global clinical research at Bristol-Myers Squibb Company focusing both in oncology global clinical research and neuroscience global clinical research. Since 2006, Vlad has also served as an associate clinical professor of psychiatry at Yale School of Medicine. Vlad completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, received his MD from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut where he received a BS degree.

Errol De Souza, PhD

Dr. De Souza is the former Executive Chairman of Bionomics Ltd. Previously, Errol held various management positions at companies including President, CEO & Director at Biodel from March 2010 to January 2016, Founder, Executive Vice President of R&D and Director at Neurocrine Biosciences from October 1992 to August 1998, President, CEO & Director at Synaptic Pharmaceutical Corporation from September 2002 to March 2003, and Senior Vice President & Head of US R&D at Hoechst Marion Roussel Pharmaceuticals and Aventis Pharmaceuticals (now Sanofi) from September 1998 to September 2002. Errol has a BA in physiology from the University of Toronto and a PhD in neuroendocrinology from the University of Toronto and was a postdoctoral fellow in neuroscience at The Johns Hopkins University School of Medicine.

Cathy Engelbert

Cathy Engelbert is the first Commissioner of the Women’s National Basketball Association (WNBA), a position she has held since July 2019. Cathy was with Deloitte for 33 years from 1986 through 2019, and held various senior positions, including as a partner serving the pharmaceutical and life sciences practice for over two decades, and then as CEO from 2015 to 2019. Cathy currently serves on the board of McDonald’s Corporation and previously served on the board of Deloitte and as the first woman chair of the Center for Audit Quality Governing Board. Cathy also served as the first woman chair of the Catalyst Board, a global non-profit organization that promotes inclusive workplaces for women. She was a founding member of the CEO Action for Diversity and Inclusion, is a Vice Chair of the Partnership for New York City and previously served as a member of the Business Roundtable, where she sat on the Education & Workforce and Immigration committees. She received a BS in accounting from Lehigh University and is a certified public accountant licensed in Pennsylvania, New York and New Jersey. Cathy has been a member of our board of directors since June 2020.

Henry A. Fernandez

Henry A. Fernandez has served as Director and Chairman of MSCI Inc. since 2007 and as Chief Executive Officer since 1998. Before leading MSCI’s transition to becoming a fully independent, public company in 2007, he was a Managing Director at Morgan Stanley from 1983 to 1991 and from 1994 to 2007, where he worked in emerging markets product strategy, equity derivative sales and trading, mergers and acquisitions, worldwide corporate finance and mortgage finance for U.S. financial institutions. Henry serves on the Board of Trustees for Stanford University as well as Memorial Sloan Kettering Cancer Center. Henry holds a Bachelor of Arts in economics from Georgetown University, an MBA from the Stanford University Graduate School of Business and pursued doctoral studies in economics at Princeton University.

David C. Hodgson

David C. Hodgson is Vice Chairman and a Managing Director of General Atlantic, a global growth private equity firm. He joined General Atlantic in 1982, helped found their partnership and has over 35 years of experience identifying and assisting portfolio companies worldwide. David has been a member of the Alignment Healthcare, Inc. Board of Directors since 2014 and the TriNet Group, Inc. Board of Directors since 2005. He is former chair and current member of the board of trustees of Johns Hopkins Medicine. David serves on the Board of Directors of Johns Hopkins HealthCare and Johns Hopkins Medicine International. David holds an AB in mathematics and social sciences from Dartmouth College and an MBA from the Stanford University Graduate School of Business.

Ted W. Love, MD

Dr. Love serves as BIO’s Chair of its Board of Directors for a two-year term (2023-2025). Previously, Ted served as President and Chief Executive Officer of Global Blood Therapeutics (GBT) as well as a member of its board from June 2014 to October 2022. From February 2010 to August 2012, he was Executive Vice President, Research and Development and Technical Operations, at Onyx Pharmaceuticals, Inc. Prior to Onyx, Ted served as President, Chief Executive Officer and Chairman of Nuvelo, Inc. Prior to Nuvelo, he served as Senior Vice President, Development, at Theravance, Inc. Earlier in his career, Ted held a number of senior management positions in medical affairs and product development at Genentech, including as Chairman of Genentech’s Product Development Committee and Vice President, Product Development. At Genentech, Ted oversaw the development strategy and execution resulting in approvals of leading therapies such as Rituxan®, Herceptin®, Xolair® and Avastin®. Dr. Love serves on the board of directors of Structure Therapeutics Inc. and Gilead Sciences, Inc.

Ted holds a BA in molecular biology from Haverford College and an MD from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.

Greg Norden

Greg Norden is the former Chief Financial Officer of Wyeth. In addition, Greg is the Managing Director of G9 Capital Group, LLC, which invests in early-stage ventures and provides corporate advisory services. Greg also serves on the Boards of Zoetis, the leading animal health company and Praxis, a clinical-stage biopharmaceutical company. Greg is a former director of Human Genome Sciences, Univision and Welch Allyn. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co, working primarily with multinational companies in the life sciences, consumer goods and financial services industries. Greg has a BS in Management and Economics from State University of New York at Plattsburgh and an MS in Accounting from LIU Post.